secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2022-09-28T23:59:59+00:00
Accession:  0000950170-22-018936
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio: RLYB212 Phase 1b rapidly eliminates HPA-1a platelets; proof-of-concept data Q1 2023
--------------------------------------------------------------------------------

- RLYB212 showed >90% reduction in mean platelet elimination half-life vs placebo in Phase 1b.
- Single subcutaneous dose eliminated transfused HPA-1a positive platelets rapidly one week after dosing.
- No serious adverse events; safety and tolerability acceptable.
- Protocol amended to increase dose and expand PK/PD sampling; registrational trial dosing expected to be informed.
- Proof-of-concept data from Phase 1b study expected in Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000095017022018936/0000950170-22-018936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000095017022018936/rlyb-20220928.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-018936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer